AI summary · may contain errors
P2RX5-FL is expressed by up to 75% of individuals with African ancestry and is stable on the plasma membrane, enabling CAR T targeting.
- Open access
Moving in Leukemia, Blood Cancer Discovery, Ophthalmology, The Lancet Haematology, Blood, JNCI: Journal of the National Cancer Institute, Journal of Clinical Oncology and JAMA Dermatology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
P2RX5-FL is expressed by up to 75% of individuals with African ancestry and is stable on the plasma membrane, enabling CAR T targeting.
AI summary · may contain errors
Overall survival in Waldenström macroglobulinemia did not change across diagnosis eras overall (p=0.64), but improved for patients aged <65 years post-2006 (median 18.8 vs 14.1 years, p=0.018).
AI summary · may contain errors
In a national cohort of 7,428 women with Hodgkin lymphoma in England and Wales, cumulative SPM incidence reached 36% by age 50, with overall invasive cancer risk elevated (SIR 3.3).
AI summary · may contain errors
In 47 primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder samples, PDCD1LG2, MTA3, CCL13, and HDAC3 are overexpressed, shaping a distinct T-follicular helper program.
AI summary · may contain errors
Safimaltib (JNJ-67856633) is a selective, allosteric MALT1 inhibitor that suppresses DLBCL and MCL cell growth at sub-micromolar doses and shows efficacy in mouse models.
AI summary · may contain errors
A 92-year-old man with prior diffuse large B-cell lymphoma developed generalized eruptive histiocytosis that mimicked lymphoma relapse, then regressed spontaneously over 3 months.
AI summary · may contain errors
Gastric MALT lymphoma risk after Helicobacter pylori eradication in Finland, Iceland, Norway, and Sweden is elevated only in years 1–5 (SIR 2.65) and normalizes by years 6–18 (SIR 0.96).
AI summary · may contain errors
A woman in her 70s with a 3-year history of extensive coral treelike telangiectasias on the trunk and lower limbs is described after prior diffuse large B-cell lymphoma of the right breast diagnosis.
AI summary · may contain errors
High HERV-K expression in diffuse large B-cell lymphoma is linked to an interferon/viral-mimicry program, and Env protein appears on the surface of a subset of cell lines.
AI summary · may contain errors
Clinically relevant chronic myeloid leukemia phenotypes emerge clearly at the pseudobulk (macrostate) level despite continuous single-cell transcriptional microstates.
AI summary · may contain errors
Glofitamab-based therapy in 84 consecutive patients with relapsed or refractory CNS lymphoma produced high response rates, with PCNSL ORR 88% and CRR 59%.
AI summary · may contain errors
Baseline FDG PET/CT detected non-central nervous system extramedullary disease in 44% of 16 adults and children with relapsed/refractory B-ALL.
AI summary · may contain errors
Quantitative CD19 density measured before CAR T-cell infusion stratifies progression-free survival in large B-cell lymphoma, with low CD19 density linked to CAR T-cell escape.
AI summary · may contain errors
TAK-007, an off-the-shelf allogeneic CD19 CAR NK-cell therapy expressing IL-15, shows encouraging response rates with an excellent safety profile in heavily pretreated B-cell lymphoma, including post-CAR-T patients, though durability is limited.
AI summary · may contain errors
RHOA loss in large B-cell lymphomas downregulates CD19 and promotes CAR-19 T-cell resistance, with RHOA deficiency present in one in six newly diagnosed cases.
AI summary · may contain errors
Lower pretreatment tumor CD19 expression measured by flow cytometry is linked to worse 1-year progression-free survival after CD19 CAR T-cell therapy in LBCL, with 16% vs 64% for CD19low vs CD19high (P = 0.005).
AI summary · may contain errors
GAK is a tumor-selective dependency in diffuse large B-cell lymphoma, and its kinase activity is required for mitotic progression, with inhibition causing G2/M arrest and cell death.
AI summary · may contain errors
In 14 patients with Sézary syndrome on mogamulizumab, CD39/CD73/CD38 ectonucleotidase profiles on CD4+ T cells track hematologic disease activity, declining with response and returning at relapse.
AI summary · may contain errors
Dual LAG-3/PD-1 blockade with IBI110 plus sintilimab in advanced alveolar soft part sarcoma achieved an overall response rate of 51.8% (14/27).
AI summary · may contain errors
EBV latent membrane proteins LMP1 and LMP2 synergize to activate MALT1 protease, with EBV-positive B-cell lines showing constitutive MALT1 activity.
AI summary · may contain errors
In a cross-sectional analysis of 534 LGLL cases and 2064 PCD cases, 20% of LGLL co-occurred with PCD, and 2% of PCD cases had LGLL.
AI summary · may contain errors
Higher abundance of an NF-κB-activated, EBV-associated tumor–inflammation niche is linked to improved survival in extranodal NK/T-cell lymphoma (ENKTL) cohorts.
AI summary · may contain errors
Frontline mantle cell lymphoma care is shifting toward biological precision, using targeted and immune-engaging therapies plus measurable residual disease to individualize treatment and reduce reliance on consolidative transplants.
Journals this month
Topics moving, week to 17 Nov 2026
By field